Organovo Announces Phase 2 Results For FXR314; Says 'Study Subjects Receiving FXR314 Achieved Statistically Significant Reduction in Liver Fat Content From Baseline'
Organovo Announces Phase 2 Results For FXR314; Says 'Study Subjects Receiving FXR314 Achieved Statistically Significant Reduction in Liver Fat Content From Baseline'
Organovo 公佈了 FXR314 的第 2 階段結果；表示 “接受 FXR314 的研究受試者肝臟脂肪含量比基準線減少了統計學上的顯著性”
Organovo Announces Phase 2 Results For FXR314; Says 'Study Subjects Receiving FXR314 Achieved Statistically Significant Reduction in Liver Fat Content From Baseline'
Organovo 公佈了 FXR314 的第 2 階段結果；表示 “接受 FXR314 的研究受試者肝臟脂肪含量比基準線減少了統計學上的顯著性”
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。